Free-text search
Content Types
-
Updated: Egetis receives SEK 5.3 billion takeover bid from US company
US-based ANI Pharmaceuticals has made a SEK 5.3 billion takeover bid for Swedish Egetis Therapeutics. Chairman Mats Blom tells Life Science Focus why the board ...
-
Lilly’s obesity ads on the underground cleared by watchdog
Eli Lilly’s advertising campaign about obesity did not breach industry rules on advertising aimed at the general public, according to a ruling by the Swedish ph...
-
Natural Cycles sharpens Nordic focus with new regional chief
After nearly a decade at Natural Cycles, Sofie Askervall has stepped into the newly created role of Head of Nordics. “Right now, we are looking closely at Norway,” she says.
-
AAX Biotech teams up with Austrian AI player on cancer antibodies
AAX Biotech is entering into a research collaboration with Austrian company Discovery Evolution. The companies will combine their technologies to develop new an...
-
Cyberattack hits French blood service
A cyberattack overnight on Sunday led to a sharp rise in temperature settings in refrigerators storing donated blood at France’s national blood service, Établis...
-
How GLP-1 drugs are changing what we buy at the supermarket
In both Sweden and Denmark, grocery industry organisations are predicting billion-krona sales losses as the use of weight-loss drugs increases. So far, however,...
-
Egetis sells FDA voucher for 190 million dollars
Swedish biotech Egetis Therapeutics is selling the priority review voucher it recently received following the U.S. approval of its drug Emcitate. The price tag ...
-
Eli Lilly drops Alzheimer’s drug candidate after phase II trial
Eli Lilly is discontinuing development of its Alzheimer’s drug candidate mevidalen. The decision follows a phase II trial that failed to meet the company’s expe...
-
Saniona moves depression drug closer to first-in-human trial
The Swedish-Danish research company Saniona has submitted an application to the FDA to begin testing its oral drug candidate in patients with major depressive disorder.
-
SynAct Pharma signs first dengue drug deal
SynAct Pharma has entered into its first commercial partnership for resomelagon as a potential treatment for dengue fever.
-
Boehringer doubles down on China with $7.4 billion deal
Boehringer Ingelheim continues to strengthen its ties with China’s growing pharmaceutical industry. The German pharmaceutical giant has now signed an agreement ...
-
Five doctors charged in Swedish prescription fraud scheme
Thirteen people, including five doctors, have been charged in a multi-million-krona fraud scheme in which a drug used to treat excessive sweating is suspected o...
-
Elfcare to integrate health data with ChatGPT – leaves sharing to users
Healthcare company Elfcare has launched a new connector that allows users to share results from its health assessments with AI assistants. Speaking to Life Scie...
-
Anna Törner: Time for new body ideals?
Why are perfectly healthy people turning to high-tech medicines to achieve outdated beauty ideals? Anna Törner asks in her latest column.
-
J&J hails early prostate cancer data as “the best we have ever seen”
A new prostate cancer pill achieved a tumour response in 75 per cent of patients whose tumours could be measured in a phase I study.
-
Roche doubles down on Chinese biotech in deal worth up to $15 billion
A year after their first antibody-drug conjugate deal, Roche and China’s Hansoh Pharmaceutical are expanding their partnership. The new agreement covers several...
-
Novo Nordisk enters billion-dollar collaboration with Orbis Medicines
Danish pharmaceutical company Novo Nordisk has entered into a strategic collaboration and licensing agreement with fellow Danish company Orbis Medicines to deve...
-
Business Development Manager at Aurevia
We are looking for an experienced Business Development Manager for a permanent, full-time position. Ideally, you are located in Skåne (Sweden) and will be part ...
-
Swedish obesity challenger halts drug programme
Swedish biotech company Empros Pharma is discontinuing its obesity drug programme. Difficulties in securing funding and growing competition from GLP-1 drugs are...
-
Sanofi strikes another multibillion-dollar deal – four candidates in focus
Sanofi and Regeneron are stepping up their long-standing partnership. The companies are now investing in four new antibody drugs in a deal that could be worth up to $8 billion.
-
He helped build Oslo Cancer Cluster – now AI is his next challenge
After 12 years, Ketil Widerberg is stepping down as General Manager of Oslo Cancer Cluster. His next move takes him to Oslo University Hospital, where he will f...
-
Orexo seeks SEK 250 million to fund pipeline and DOJ settlement
Orexo had SEK 118.7 million in available cash at the end of August. The Uppsala-based company now wants to raise a further SEK 250 million to fund its developme...
-
LEO Pharma acquires dermatology drug for 435 million USD
LEO Pharma strengthens its dermatology portfolio by acquiring the late-stage drug candidate dersimelagon.
-
Russian lab worker’s death sparks suspected plague investigation
Russian authorities have placed around 200 people under medical observation amid suspicions of plague, following the death of a 28-year-old laboratory worker in...
BREAKING